Expression of Interleukin 8 and Its Receptors in Human Colon Carcinoma Cells with Different Metastatic Potentials

Aihua Li, Michelle L. Varney, and Rakesh K. Singh

INTRODUCTION

IL-8 is a member of the chemokine superfamily of structurally and functionally related inflammatory cytokines that stimulate the migration of distinct sets of cells including neutrophils, monocytes, lymphocytes, and fibroblasts (1–4). CXCR1 and CXCR2, also named IL-8RA and IL-8RB, are receptors for IL-8. CXCR1 and CXCR2 both bind IL-8 with high affinity, but CXCR2 also binds to other CXC chemokines (5–9). Recent studies demonstrated that IL-8 regulates tumor cell growth and metastasis in melanoma (10), carcinoma cells of lung, stomach, pancreas, liver, gall bladder (11, 12), and prostate cancer (13). It also regulates angiogenesis in human bronchogenic carcinoma (14), squamous cell carcinoma (15), and non-small cell lung carcinoma in nude mice (16). Expression of CXCR1 and CXCR2 receptors was found in keratinocytes, fibroblasts, endothelial cells, melanoma, and colon cancer cells (9, 11, 17, 18). These receptors have also been implicated in angiogenic responses to IL-8 and neutrophil and lymphocyte migration (5, 7, 9, 17, 19).

Metastasis is a complex process influenced by genetic, biochemical, immunological, and biological changes and influenced by tumor-host interaction (20). Several growth factors and cancer-associated genes, such as epidermal growth factor, carcinoembryonic antigen, and type IV collagenase, are involved in colon carcinoma metastases (21). We have reported that IL-8 expression correlates with tumor growth and metastatic potential in melanoma cells (10, 22, 23). Recently, several studies report that IL-8 up-regulates inflammatory responses, tumor cell proliferation, and migration in colon epithelial cell lines (17, 24–26). However, whether the expression of IL-8 is related to the metastatic potential in colon carcinoma cells remains unclear.

The purpose of this study was to examine the expression of IL-8 and its receptors in colon carcinoma cells with different metastatic potentials and determine the role of IL-8 in modulating phenotypes associated with tumor progression and metastasis. We examined the expression of IL-8, CXCR1, and CXCR2 and their roles in proliferation of colon carcinoma cells with different metastatic potentials. Our data suggested that constitutive expression of IL-8 in colon carcinoma cells is associated with metastatic potential. Furthermore, these studies demonstrated that IL-8 might act as an autocrine/paracrine growth factor in colon cancer progression and metastasis.

MATERIALS AND METHODS

Cell Lines and Reagents. The human Caco2 cell line isolated from primary colonic tumor (27, 28) was obtained from...
American Type Tissue Culture (ATCC, Manassas, VA). The heterogeneous low metastatic human KM12C cell line was originally established in culture from a Duke’s stage B2 primary tumor surgical specimen (29, 30). The high metastatic KM12L4 cell line is a subclone derived from KM12C in nude mice (29). Human umbilical vein endothelial cells (HUVEC) were obtained from American Type Culture Collection. The cell lines were maintained in culture as an adherent monolayer in MEM supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, l-glutamine, 2-fold vitamin solution, and gentamicin (Life Technologies, Inc., Gaithersburg, MD). HUVECs were additionally supplemented with bFGF and endothelial cell growth factor. All cultures were free of Mycoplasma and pathogenic murine viruses. Cultures were maintained for no longer than 4 weeks after recovery from frozen stocks.

**ELISA for Human IL-8.** IL-8 levels in culture supernatants were determined using ELISA-paired antibodies purchased from Endogen, Inc. (Woburn, MA). This assay is a quantitative “sandwich” enzyme immunoassay. One hundred μl of the primary monoclonal antibody against IL-8 (2 μg/ml) were coated in Nunc Maxisorp plates in each well. After overnight incubation at 4°C, the plates were washed and blocked for 1 h with blocking buffer (4% BSA in PBS). After the plates were washed four times, 50 μl of culture supernatant or recombinant IL-8 protein at different concentrations (Endogen, Inc.) and 50 μl of biotinylated IL-8 antibody were added to each well. After 2 h of incubation, the plates were washed, and the immunoreactivity was determined using the avidin-HRP-TMB detection system (Dako Corp., Carpinteria, CA). The reactions were stopped by addition of 50 μl of 0.18 N H2SO4 and absorbance was determined using an ELISA microtiter plate reader (Bio-Tek Instruments, Inc., Winooski, VT) at 450 nm. A curve of the absorbance versus the concentration of IL-8 in the standard wells was plotted. By comparing the absorbance of the samples to the standard curve, we determined the concentration of IL-8 in the unknown samples.

**Analysis by ICC.** CXCR1 and CXCR2 expression by colon carcinoma cells with different metastatic potentials was analyzed by ICC. Briefly, cells (1 × 105) were plated into four-well chamber slides (Nunc, Inc., Naperville, IL). The cells were cultured for 72 h and used for immunostaining. Slides were washed twice with PBS and fixed with 4% glutaraldehyde for 10 min. After washing twice with PBS, cells were incubated with a blocking solution containing 5% normal horse serum in PBS for 20 min at room temperature. Excess blocking solution was drained, and samples were incubated with a 1:200 dilution of anti-CXCR1 or anti-CXCR2 antibodies (PharMingen, San Diego, CA) overnight at 4°C in a humidified chamber. The samples were then rinsed four times with PBS and incubated with a 1:500 dilution of biotinylated horse anti-mouse/rabbit IgG (Vector Laboratories, Burlingame, CA). The immunoreactivity was detected using the ABC Elite kit and 3,3′-diaminobenzidine substrate kit (Vector Laboratories) according to manufacturer’s instructions. A reddish-brown precipitate in the cytoplasm indicated a positive reaction. Negative controls used all reagents except the primary antibody.

**mRNA Analysis.** Total cellular RNA was isolated from colon carcinoma cell lines (1 × 106 cells) using Trizol reagent (Life Technologies, Inc.). RT-PCR was performed as described earlier (31), and cDNAs were synthesized using total RNA (2 μg), oligo(dT)12-18 primer, and superscript RT (Life Technologies, Inc.). Two μl of first-strand CDNA (1:10 dilutions) were amplified using PCR primer sets: IL-8 sense, ACA TAC TCC AAA CCT TAC CAC CC; IL-8 antisense, CAA CCC TCT GCA CCC AGT TTT C; CXCR1 sense, GAG CCC CGA ATC TGA CAT TA; CXCR1 antisense, GAG CCC CGA ATC TGA CAT TA; CXCR2 sense, ATT CTG GGC ATC CTT CAC AG; CXCR2 antisense, TGC ACT TAG GCA GGA GGT CT; β-actin sense, TGA AGT GTG ACG TGG ACA TC; and β-actin antisense, ACT CGT CAT ACT CCT GCT TG, and DNA thermal cycler (Perkin-Elmer, Foster City, CA) for different cycles. Each cycle set used a denaturing temperature (94°C) for 60 s, annealing temperatures (57°C) for 90 s, and extension temperature (72°C) for 90 s for a total of 35 cycles for β-actin and 40 cycles for the other genes. PCR fragments were separated on a 2% agarose gel containing ethidium bromide (0.5 μg/ml), visualized, and photographed, and relative intensity of the specific gene expression was determined using Alpha-Image Analysis system (Alpha Innotech, San Leandro, CA). Gene expression was expressed as expression index, the ratio of each signal to the signal from the housekeeping gene β-actin.

**In Vitro Proliferation Assay.** Colon carcinoma cells (5 × 103) were seeded into 38-mm2 wells of 96-well flat-bottomed plates in quadruplicate and allowed to adhere overnight. The cultures were then washed and refed with medium alone (control) or medium containing different treatments for the duration of incubation. After treatment, proliferative activity was determined by the MTT assay (32) using a microtiter plate reader (Bio-Tek Instruments, Inc., Winooski, VT) at 570 nm. Growth stimulation/inhibition was calculated as the percentage of growth stimulation/inhibition: [1 – (A/B)] × 100, where A is the absorbance of treated cells, and B is the absorbance in untreated control cells.

**Migration Assay.** Colon carcinoma cell migration in response to IL-8 was determined as described earlier (33, 34). Transwell chambers (6.5 mm; Corning Costar Corp., Cambridge, MA) with polycarbonate membrane containing 8.0 μm pores were coated with Matrigel (Collaborative Biomedical, Bedford, MA). Colon carcinoma cells (5 × 103) were plated onto Transwell chambers with medium (serum-free) alone or medium containing fibroblast cell conditioned medium (positive control) in duplicate and incubated at 37°C in 5% CO2 incubator for 4 h. MTT was added, and cells were incubated for an additional 2 h. Cells from the top of the Transwell chambers were removed using cotton swab (residual cells). Cotton swabs containing residual cells and Transwell chamber (migrated cells) were placed in 24-well plates containing 400 μl of DMSO. After 1 h of gentle shaking, 100 μl of samples were removed, and absorbance was determined at 570 nm using an ELISA plate reader. The percentage of migratory activity was calculated as: percentage of migration = A/[A + B] × 100, where A is the absorbance of migrated cells, and B is the absorbance of residual cells.

**Adhesion of Tumor Cells to Endothelial Cell Assay.** 51Cr-labeled tumor cells (1 × 105) were added to confluent HUVEC-coated wells (96-well plate) in quadruplicate and incubated with medium alone or medium containing different treatments for 2 h. Nonadherent cells were removed by washing twice with PBS and lysed with 1% SDS, and the residual
radioactivity was analyzed using a gamma counter (Packard, Downers Grove, IL). The percent of binding is: 
\[
\frac{A}{B} \times 100
\]
where \(A\) is the cpm of treated cells, and \(B\) is the cpm in untreated control cells.

**Statistical Analysis.** The significance of the data was determined by the Student’s \(t\) test (two-tailed) using SPSS software (SPSS, Inc., Chicago, IL). \(P < 0.05\) was deemed significant.

**RESULTS**

**Expression of IL-8 in Colon Carcinoma Cells.** In the first set of experiments, we analyzed the production of IL-8 protein in human colon carcinoma cells with different metastatic potentials. Cell-free culture supernatant was harvested from \(1 \times 10^5\) cells with 24 h culture, and IL-8 protein level was determined by ELISA. Very low levels of IL-8 protein were detected in Caco2 cells (1.7 pg/ml; Fig. 1). High metastatic KM12L4 cells expressed the highest level of IL-8 protein (758 pg/ml), whereas low metastatic KM12C cells expressed lower levels of IL-8 (137 pg/ml; Fig. 1; \(P < 0.05\)).

Next, we analyzed the mRNA expression of IL-8 in non-metastatic and low and high metastatic colon carcinoma cell lines by RT-PCR (Fig. 2A). Total cellular RNA was isolated from \(1 \times 10^6\) cultured cells. The mRNA expression level of IL-8 was quantitated as an expression index (Fig. 2B). We did not observe IL-8 mRNA expression in Caco2 cells, whereas IL-8 mRNA levels were higher in KM12L4 than in KM12C cells. Different IL-8 protein levels and mRNA expression suggest that constitutive expression of IL-8 in human colon carcinoma cells correlates with metastatic potential.

**Expression of CXCR1 and CXCR2 in Colon Carcinoma Cells.** In the next set of experiments, we analyzed the expression of CXCR1 and CXCR2 by ICC (protein) and RT-PCR (mRNA). Colon carcinoma cells (\(1 \times 10^5\) cells/ml) were plated on four-well chamber slides. After 72 h culture, cells were fixed and immunostained with anti-CXCR1 or anti-CXCR2 antibodies. A heterogeneous pattern of CXCR1 as well as CXCR2 immunoreactivity was detected in the three colon carcinoma cell lines with different metastatic potentials (Fig. 3). Less than 10% of Caco2 cells showed CXCR1 or CXCR2 immunoreactivity. CXCR1 immunoreactivity was observed in 40% of KM12C and KM12L4 cells, whereas >60% of KM12C or KM12L4 cells bound to anti-CXCR2. Thus, expression of CXCR1 and CXCR2 was lower in Caco2 cells compared with KM12C and KM12L4 cells. We did not observe a difference in immunostaining intensity between KM12C (low metastatic) and KM12L4 (high metastatic) cells. RT-PCR analysis demonstrated that high metastatic KM12L4 cells expressed high levels of CXCR1 and CXCR2 mRNA, compared with low metastatic or nonmetastatic KM12C and Caco2 cells (Fig. 2). These data suggest that colon carcinoma cells with different metastatic potentials differentially express receptors for IL-8.

**Fig. 1** Expression of IL-8 protein in human colon carcinoma cells with different metastatic potentials. Culture supernatants were harvested from \(1 \times 10^5\) cells after 24 h of incubation and analyzed by ELISA. The values are means of triplicate cultures; bars, SE. This is a representative of two experiments done in triplicate. * significantly different from Caco2 cells (\(P < 0.05\)).

**Fig. 2** Expression of IL-8, CXCR1, and CXCR2 mRNA in human colon carcinoma cells with different metastatic potentials. A, representative agarose-gel photograph showing IL-8, CXCR1, and CXCR2 specific mRNA transcripts amplified using RT-PCR. B, quantitative representation of the levels of IL-8, CXCR1, and CXCR2 mRNA. The values are presented as expression indices calculated by comparing the levels of intensity for the specific gene to the housekeeping gene \(\beta\)-actin. This is a representative of three experiments with similar results.
Inhibition of IL-8-induced Proliferation by Antibody to IL-8, CXCR1, and CXCR2. To determine the function of the constitutive IL-8 expression in colon carcinoma cells, we examined whether autocrine IL-8 production and/or activity regulates colon cancer cell proliferation. KM12C (low IL-8 producer) and KM12L4 (high IL-8 producer) colon cancer cells (5000/well) were plated into 96-well plates in medium alone or medium containing neutralizing antibodies to IL-8, CXCR1, or CXCR2. Antibodies of the same isotype were used as a control. Colon carcinoma cell proliferation was inhibited by anti-IL-8, anti-CXCR1, or anti-CXCR2 in both KM12C and KM12L4 cells (Fig. 4). The percentage of inhibition ranged from 15.7 to 27.9% (Fig. 4). Effective inhibition of cell proliferation by antibodies to IL-8 and receptors CXCR1 and CXCR2 suggests that IL-8 might be an autocrine growth factor for human colon cancer cells.

Induction of Colon Carcinoma Cell Proliferation by IL-8. In the next set of experiments, we determined whether the exogenous addition of IL-8 regulates colon carcinoma cell proliferation. Caco2 (non-), KM12C (low), and KM12L4 (high) cells were incubated in medium alone or medium containing different concentrations of recombinant human IL-8. Caco2, KM12C, and KM12L4 cells treated with IL-8 showed increased cell proliferation (Table 1; Fig. 5). Stimulation of proliferation was higher in Caco2 (low IL-8 producer) or KM12C (low IL-8 producer) than in KM12L4 (high IL-8 producer) cells (Table 1). These data suggest that recombinant human IL-8 induced Caco2 and KM12C cell proliferation in a concentration-dependent manner, and their response is inversely associated with levels of IL-8 produced by these cells.

Differential Migratory Potential of Colon Carcinoma Cells. We determined the putative role of IL-8 expression on the invasive potential of human colon carcinoma cells with different metastatic potentials. KM12C (low IL-8 expression) and KM12L4 (high IL-8 expression) were cultured in Matrigel-coated 8-μm-pore size Transwell chambers, and their migratory potential was determined. The percentage of migration was higher in KM12L4 cells (39.2 ± 6.7) as compared with KM12C cells (19.4 ± 3.5), suggesting an association between IL-8 expression and aggressiveness in colon carcinoma cells.

Table 1  IL-8 induced stimulation of cell proliferation of human colon carcinoma cells with different metastatic potentials expressing different levels of IL-8

<table>
<thead>
<tr>
<th>IL-8 (ng/ml)</th>
<th>Caco2</th>
<th>KM12C</th>
<th>KM12L4</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0001</td>
<td>46.05 ± 13.89</td>
<td>22.74 ± 5.39</td>
<td>12.09 ± 3.86</td>
</tr>
<tr>
<td>0.001</td>
<td>34.19 ± 15.689</td>
<td>50.67 ± 5.35</td>
<td>17.16 ± 3.92</td>
</tr>
<tr>
<td>0.01</td>
<td>82.16 ± 16.73</td>
<td>40.95 ± 5.49</td>
<td>−0.99 ± 8.05</td>
</tr>
<tr>
<td>0.1</td>
<td>94.85 ± 19.21</td>
<td>55.49 ± 8.53</td>
<td>7.43 ± 7.12</td>
</tr>
<tr>
<td>1</td>
<td>105.22 ± 27.4</td>
<td>73.55 ± 21.69</td>
<td>5.23 ± 5.42</td>
</tr>
<tr>
<td>10</td>
<td>87.39 ± 16.02</td>
<td>48.87 ± 6.87</td>
<td>26.48 ± 2.05</td>
</tr>
<tr>
<td>100</td>
<td>100.98 ± 13.97</td>
<td>43.66 ± 9.43</td>
<td>7.82 ± 5.77</td>
</tr>
</tbody>
</table>

*Significantly different from KM12L4 cells expressing high levels of IL-8 at the corresponding concentrations of exogenously added recombinant IL-8 (P < 0.05).
Inhibition of Colon Carcinoma Cells Binding to Endothelial Cells. To determine the role of IL-8 in tumor-endothelial cell interaction, adhesion of colon carcinoma cells to HUVECs was examined. $^{51}$Cr-labeled Caco2 and KM12C cells were plated on HUVEC-coated wells in the presence or absence of recombinant human IL-8. Treatment of cells with recombinant IL-8 enhanced colon carcinoma cells binding to HUVECs. The binding stimulation by IL-8 was $50\%$ in low metastatic KM12C cells (Fig. 6A). In another set of experiments, we determined the autocrine role of IL-8 production in colon carcinoma-endothelial cell interaction by using high IL-8-producing KM12L4 cells and neutralizing antibodies against IL-8, CXCR1, and CXCR2 in different combinations. Binding of KM12L4 cells to HUVECs was inhibited by anti-IL-8, anti-CXCR1, and anti-CXCR2 alone or anti-IL-8 in combination with anti-CXCR1 and/or anti-CXCR2 (Fig. 6B). These results suggest a relationship between IL-8 and metastasis in colon carcinoma.

DISCUSSION

We observed a differential expression of IL-8 and its receptors, CXCR1 and CXCR2, in human colon carcinoma cells with different metastatic potentials. IL-8 protein and mRNA expression was significantly lower in nonmetastatic and low metastatic colon carcinoma cells than in high metastatic colon carcinoma cells, suggesting an association with metastatic potential. The expression of CXCR1 and CXCR2 protein and mRNA was lower in nonmetastatic Caco2 cells as compared with metastatic KM12C and KM12L4 cells. Exogenous recombinant IL-8 induced cell proliferation in colon carcinoma cells. Neutralizing anti-IL-8, anti-CXCR1, and anti-CXCR2 showed inhibition of cell proliferation in both KM12C and KM12L4 cells. Studies have reported that IL-8 regulates cell proliferation and angiogenesis in various tumors (10–18). Our data suggest that expression of IL-8 in colon carcinoma cells might play an important role in growth and metastasis. These data also confirm a recent study (23) that reports that IL-8 can be an autocrine factor, playing a role in colon carcinoma growth.

Primary malignant neoplasms consist of cells with different metastatic potentials expressing different levels of genes regulating metastatic phenotype (20, 35). KM12L4 is a high metastatic subclone from low metastatic KM12C cells. In the present study, we observed different IL-8 mRNA and protein expression among the three colon carcinoma cell lines with different metastatic potentials. Our data suggest that colon carcinoma cells with different metastatic potentials, constitutively expressing different levels of IL-8, respond differently to exogenous IL-8. Furthermore, neutralizing antibodies to IL-8 and its receptors inhibited the proliferation of colon carcinoma cells, suggesting that IL-8 may act as an autocrine growth factor and may contribute to metastatic potential in colon carcinoma cells.

IL-8 can bind two receptors, CXCR1 and CXCR2. CXCR1 only binds IL-8, whereas CXCR2 binds IL-8 and several other CXC chemokines (5–9). These receptors have been shown to play an important role in angiogenesis and tumor progression (3, 5, 7, 9, 36). In this study, different CXCR1 and CXCR2 mRNA and protein expression was observed in colon carcinoma cells in accordance with metastatic potential. In addition, antibodies to
CXCR1 and CXCR2 showed significant inhibition of cell proliferation in both KM12C and KM12L4 cells. These data suggest that inhibition of IL-8 production and/or activity can inhibit proliferation of colon carcinoma cells, and IL-8 may act as an autocrine or paracrine growth factor.

Tumor-endothelial cell interaction is important for tumor invasion and metastasis (37–39). A key event in cancer metastasis is transendothelial migration of tumor cells (40). This process involves multiple adhesive interactions between tumor cells and endothelial cells (35, 38). In the present study, we observed that recombinant human IL-8 enhanced adherence of colon carcinoma cells to endothelial cells. In addition, neutralization of IL-8 activity by antibodies to IL-8 and its receptors inhibited tumor cell adherence to endothelial cells in high metastatic KM12L4 cells producing higher levels of IL-8. These studies provide an additional evidence for the role of IL-8 in modulating phenotypes associated with metastasis. However, it is not clear whether IL-8-mediated regulation of adherence of colon carcinoma cells to endothelial cells requires a specific set of adhesion molecules. Studies are in progress to determine the role of adhesion molecules in IL-8-mediated tumor-endothelial cell interaction and transendothelial migration.

Our laboratory and others have demonstrated that IL-8 expression by malignant cells can induce the proliferation of tumor cells in an autocrine manner and induce angiogenesis, migration, and collagenase production, all of which are important steps in tumor growth and metastasis (23, 25, 41, 42). Several studies have reported that IL-8 regulates cell migration (25), proliferation, and angiogenesis in colon carcinoma cells (24, 25). Serum levels of IL-8 in colon cancer patients were significantly increased in patients with metastasis (43). The present study showed that constitutive expression of IL-8 in colon carcinoma cells correlated with different metastatic potentials.

In summary, we demonstrated a correlation between constitutive expression of IL-8 and its receptors in colon carcinoma cells with different metastatic potentials. Our data suggest that IL-8 may act as an autocrine/paracrine growth factor in colon carcinoma cells and modulate phenotypes associated with tumor growth and metastasis.

ACKNOWLEDGMENTS

We thank Lisa Chudomelka for editorial assistance.

REFERENCES


Expression of Interleukin 8 and Its Receptors in Human Colon Carcinoma Cells with Different Metastatic Potentials

Aihua Li, Michelle L. Varney and Rakesh K. Singh


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/7/10/3298

Cited articles
This article cites 39 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/7/10/3298.full.html#ref-list-1

Citing articles
This article has been cited by 23 HighWire-hosted articles. Access the articles at:
/content/7/10/3298.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.